A Study of the Safety and Efficacy of a New Treatment for Diabetic Macular Edema

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Allergan
ClinicalTrials.gov Identifier:
NCT00168389
First received: September 12, 2005
Last updated: June 21, 2013
Last verified: June 2013
  Purpose

This study will evaluate the safety and efficacy of an intravitreal implant of dexamethasone for the treatment of diabetic macular edema.


Condition Intervention Phase
Diabetic Macular Edema
Drug: Dexamethasone
Drug: Sham
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Allergan:

Primary Outcome Measures:
  • Percentage of Patients with Best Corrected Visual Acuity (BCVA) Improvement ≥ 15 Letters from Baseline [ Time Frame: Baseline, 36 Months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Change from Baseline in BCVA [ Time Frame: Baseline, 36 Months ] [ Designated as safety issue: No ]
  • Contrast Sensitivity [ Time Frame: 36 Months ] [ Designated as safety issue: No ]
  • Vessel Leakage as Measured by Fluorescein Angiography(FA) [ Time Frame: 36 Months ] [ Designated as safety issue: No ]
  • Retinal Thickness as Measured by Optical Coherence Tomography (OCT) [ Time Frame: 36 Months ] [ Designated as safety issue: No ]

Enrollment: 494
Study Start Date: February 2005
Study Completion Date: June 2012
Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Dexamethasone 700 μg
700 µg Dexamethasone posterior segment drug delivery system - injection into the vitreous cavity every 6 months for 36 months.
Drug: Dexamethasone
350 µg or 700 µg Dexamethasone posterior segment drug delivery system - injection into the vitreous cavity every 6 months for 36 months.
Other Names:
  • Posurdex®
  • Ozurdex®
Experimental: Dexamethasone 350 μg
350 µg Dexamethasone posterior segment delivery system - injection into vitreous cavity every 6 months for 36 months.
Drug: Dexamethasone
350 µg or 700 µg Dexamethasone posterior segment drug delivery system - injection into the vitreous cavity every 6 months for 36 months.
Other Names:
  • Posurdex®
  • Ozurdex®
Sham Comparator: Sham
Sham posterior segment drug delivery system - needle-less drug delivery system without study medication at 6 month intervals for 36 months.
Drug: Sham
Sham posterior segment drug delivery system - needle-less drug delivery system without study medication at 6 month intervals for 36 months.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  • 18 years of age or older with diabetic macular edema;
  • Decrease in visual acuity in at least one eye as a result of macular edema (20/50 or worse);
  • Visual acuity in other eye no worse than 20/200

Key Exclusion Criteria:

  • Known anticipated need for ocular surgery within first 12 months of study;
  • History of glaucoma or current high eye pressure requiring more than 1 medication;
  • Uncontrolled systemic disease;
  • Known steroid-responder;
  • Use of systemic steroids
  • Use of Warfarin/Heparin
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00168389

Locations
United States, California
Los Angeles, California, United States
Australia, New South Wales
Westmead, New South Wales, Australia
Canada, Ontario
Toronto, Ontario, Canada
Czech Republic
Prague, Czech Republic
Germany
Hamburg, Germany
Israel
Tel Aviv, Israel
Philippines
Rockwell Center, Makati, Philippines
Portugal
Coimbra, Portugal
South Africa
Cape Town, South Africa
Spain
Barcelona, Spain
Sponsors and Collaborators
Allergan
Investigators
Study Director: Medical Director Allergan
  More Information

No publications provided

Responsible Party: Allergan
ClinicalTrials.gov Identifier: NCT00168389     History of Changes
Other Study ID Numbers: 206207-010
Study First Received: September 12, 2005
Last Updated: June 21, 2013
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Edema
Macular Edema
Signs and Symptoms
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases
Dexamethasone acetate
Dexamethasone
Dexamethasone 21-phosphate
BB 1101
Anti-Inflammatory Agents
Therapeutic Uses
Pharmacologic Actions
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Central Nervous System Agents
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on April 16, 2014